H Michels1. 1. FKH, Abteilung für Kinder- und Jugendrheumatologie Im Spitzerfeld 25 69151 Neckargemünd, Germany.
Abstract
OBJECTIVE: To determine pediatric rheumatologists' personal definitions of systemic low-dose, long-term (> 4 weeks) corticosteroid therapy of juvenile idiopathic arthritis (JIA). METHODS: Pediatric rheumatologists from America, the Near East (Israel), Australia and Europe were asked for their personal definition of a low-dose long-term corticosteroid therapy of JIA with the aid a standardized questionnaire. RESULTS: Of 99 questionnaires returned, 92 were evaluable. The dosage still considered low turned out to be 0.26 +/- 0.14 mg prednisolone/kgBW/day (min-max = 0.04-0.50 mg, n = 92). Higher dosages were indicated from Northern Europe (0.29 +/- 0.12, n = 9), Western Europe (0.42 +/- 0.14, n = 7), Southern Europe (0.30 +/- 0.14, n = 9), Eastern Europe (0.25 +/- 0.14, n = 6) and North America (0.33 +/- 0.17, n = 16) than from Central Europe (0.19 +/- 0.09, n = 43). CONCLUSION: Pediatric rheumatologists' personal definitions of low-dose, long-term corticosteroid therapy vary within a wide range. The reason for these differences and the impact on patients should be investigated. In addition, a generally accepted definition for low-dose, long-term corticosteroid therapy should be developed and subsequently examined in studies.
OBJECTIVE: To determine pediatric rheumatologists' personal definitions of systemic low-dose, long-term (> 4 weeks) corticosteroid therapy of juvenile idiopathic arthritis (JIA). METHODS: Pediatric rheumatologists from America, the Near East (Israel), Australia and Europe were asked for their personal definition of a low-dose long-term corticosteroid therapy of JIA with the aid a standardized questionnaire. RESULTS: Of 99 questionnaires returned, 92 were evaluable. The dosage still considered low turned out to be 0.26 +/- 0.14 mg prednisolone/kgBW/day (min-max = 0.04-0.50 mg, n = 92). Higher dosages were indicated from Northern Europe (0.29 +/- 0.12, n = 9), Western Europe (0.42 +/- 0.14, n = 7), Southern Europe (0.30 +/- 0.14, n = 9), Eastern Europe (0.25 +/- 0.14, n = 6) and North America (0.33 +/- 0.17, n = 16) than from Central Europe (0.19 +/- 0.09, n = 43). CONCLUSION: Pediatric rheumatologists' personal definitions of low-dose, long-term corticosteroid therapy vary within a wide range. The reason for these differences and the impact on patients should be investigated. In addition, a generally accepted definition for low-dose, long-term corticosteroid therapy should be developed and subsequently examined in studies.
Authors: Ashley P Jones; Dannii Clayton; Gloria Nkhoma; Frances C Sherratt; Matthew Peak; Simon R Stones; Louise Roper; Bridget Young; Flora McErlane; Tracy Moitt; Athimalaipet V Ramanan; Helen E Foster; Paula R Williamson; Samundeeswari Deepak; Michael W Beresford; Eileen M Baildam Journal: Health Technol Assess Date: 2020-07 Impact factor: 4.014